Forging a position as an innovative player in
infectious disease vaccines and therapies

About Our Disease Targets

We use our in-house expertise in development of therapeutics and in infectious disease plus our extensive partnership network to identify the best cost-effective commercial opportunities for portfolio value growth.

The focus on infectious diseases is timely. The worldwide anti-infectives market was worth more than US$53 billion in 2011 and has been projected to reach an astounding US$103 billion in 2015. Anti-infectives include the sales of antivirals, antifungals and antibacterials worldwide.

BioDiem’s development work currently focuses on the following key disease targets:

Influenza: influenza is caused by a virus and is highly contagious. Illness can result in hospitalisation and death especially in the high-risk groups (children, elderly or chronically ill). Worldwide the annual epidemics are estimated to result in 3-5 million cases of severe illness, and about 250,000 to 500,000 deaths. Circulating flu virus strains can change and so vaccinations maybe required each year.

Tuberculosis:  TB is an  infection caused by a bacteria. Resistance to TB drugs is a global concern. TB commonly affects the lungs but can also affect other parts of the body. It is spread by droplets from the throat and lungs of infected people. It is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent. In 2013, 9 million fell ill with TB, and 1.5 million died from TB. It is a leading killer of HIV-positive patients with an estimated one quarter of all HIV-related deaths caused by TB.

Sexually transmitted infection (STI): Trichomonas vaginalis, is the microorganism commonly responsible for the STI trichomoniasis. Trichomoniasis is an extremely common infection which usually causes inflammation and irritation of the urogenitary tract. Infection with trichomoniasis has been associated with increased likelihood of the development of some cancers, HIV infection and reproductive issues.

Serious bacterial infections, including Methicillin-resistant Staphylococcus aureus (MRSA): a strain of antibiotic-resistant bacteria of huge concern to global healthcare systems. The treatment options for this Golden Staph are increasingly limited as the resistant form spreads.

Invasive fungal infections, including Aspergillosis:  fungal infections are growing problem in critically ill patients and an important cause of illness and death in patients being treated for cancers or in other diseases where the immune system is severely weakened by the disease or its treatments. Previously rare disease-causing fungi have emerged. Fungal infections can be resistant to current treatments. For example Aspergillosis can be difficult to cure and can prove fatal. Invasive aspergillosis is associated with a mortality rate of 30-95%. [1]